Midatech Pharma Share Discussion Threads

[yus777] 31/8/2021 12:16

100k buy at 25.9p strap your seatbelts on the up now

[escapetohome] 15/7/2021 13:04

An unacceptable level of dilution, stephen.

[daniel] 15/7/2021 12:13

Well, It's important for the Directors to be aware that they have issued 40% of the company's shares capital in the past 1 month. While the award to Dmitry is acceptable, I don't feel the same about Stephen's exercise price of 27.75 pence per share. The share price has fallen too far, and shareholders are in massive losses without recourse to share options. The Board needs to realize that the company is grossly undervalued, and they need to fast-track commercialization and bring in new investors into the company. Thank you.

[pdt] 13/7/2021 07:42

Interesting new appoitment. He was Chief Medical Officer of Oxford Biomedica plc, a £1.1 billion market cap company to move here, a £18m market cap company. Presumably he sees some potential here?

[tomboyb] 12/7/2021 14:32

RNS Number : 9657E

Midatech Pharma PLC

12 July 2021

12 July 2021

Midatech Pharma PLC

("Midatech" or the "Company")

Midatech Strengthens Management Team

with

Appointment of Dr Dmitry Zamoryakhin as Chief Scientific Officer

Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role, with immediate effect.

Dr Zamoryakhin has broad experience across all phases of development of drugs and medical devices, working with regulatory authorities including the EMA, FDA, PMDA, and NMPA. Most recently, he was Chief Medical Officer of Oxford Biomedica plc (LON: OXB), having previously held positions of increasing responsibility at Grunenthal GmbH, Daiichi Sankyo Company Limited (TYO: 4568), Ono Pharmaceutical Co., Limited (TYO: 4528) and GlaxoSmithKline plc (LON:GSK, NYSE: GSK). He qualified as a doctor of medicine at Perm State Medical Academy, Russia, before earning a diploma in Pharmaceutical Medicine at PHARMED, Universite Libre de Bruxelles, and an MBA at Warwick Business School.

Dr Zamoryakhin will take over from Steve Damment, EVP R&D who, after six years with the Company, has decided to retire from full-time employment at the end of September 2021.

Commenting, Stephen Stamp, CEO and CFO of Midatech said : "I am delighted to welcome Dmitry to the Midatech team. He is a medic, was big pharma trained and has been biotech battle hardened. His breadth of experience will be invaluable as we move our Q-Sphera programmes and MTX110 through proof of concept to partnering.

"On behalf of everybody at Midatech, I should also like to express our thanks to Steve Damment for his service to the Company and, in particular, the key role he has played in championing MTX110."

For more information, please contact:

[escapetohome] 05/7/2021 20:33

Very very interesting, thanks for posting.

[pdt] 05/7/2021 14:29

Interesting potential platform technology in respect of Q-Sphera and mAbs. I have just bought a small amount and will keep an eye on how things develop before adding.

I see a new article on the website but it gives no new information.

[daniel] 29/6/2021 08:28

Midatech Pharma PLC

("Midatech" or the "Company")

UK Placing to Raise GBP10.0 million

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has raised GBP10.0 million (before expenses) by way of a placing to investors in the UK ("Placing") of 35,087,720 new ordinary shares of 0.1p each ("Placing Shares") at an issue price of GBP0.285 per Placing Share ("Issue Price"). The Placing brings new UK institutions into the Company's shareholder base. Turner Pope Investments (TPI) Limited ("Turner Pope") acted as sole bookrunner for the Placing. Turner Pope participated in the Placing.

The Issue Price of the Placing Shares represents a discount of approximately 12.3% to the closing middle market price of GBP0.325 per existing ordinary share on 28 June 2021, being the last business day before this announcement. The Placing Shares represent approximately 35.6% of the issued share capital of the Company as enlarged by the Placing.

The allotment of the Placing Shares is being made pursuant to existing authorities to allot shares and other relevant securities and to disapply pre-emption rights under section 551 of the Companies Act 2006, which the Directors were given at the Company's General Meeting held on 2 March 2020.

Background to the Placing

On 17 June 2021, the Company announced a series of updates to its R&D programmes including:

-- data that demonstrate the Company has been able to encapsulate an exemplar monoclonal antibody ("mAb") using its Q-Sphera technology while preserving its functional integrity and antigen binding;

-- delivery of proof of concept Q-Sphera formulations of MTX214 and MTX216 for the Company's collaboration partner to initiate in vivo IND-enabling studies;

-- in vivo data to support a three month dosing interval for MTD211, the Company's formulation of long-acting brexpiprazole;

-- start up activities for a Phase II study of MTX110 in Diffuse Intrinsic Pontine Glioma ("DIPG") following a positive pre-IND meeting with the FDA; and

-- planning for a Phase I pilot study of MTX110 in Glioblastoma Multiforme ("GBM") following encouraging preclinical data which demonstrate the potency of MTX110 in multiple patient-derived GBM cell lines.

Use of Proceeds

The proceeds of the Placing, net of fees and expenses, are expected to be approximately GBP9.0 million ("Net Proceeds"). We expect the Net Proceeds will be used to:

-- develop, to proof of concept stage, additional mAb formulations using the Company's Q-Sphera technology following the success with the exemplar mAb disclosed as part of the Company's R&D update on 17 June 2021;

-- add new small molecule Q-Sphera programmes to the Company's internal pipeline;
-- initiate a Phase II clinical study of MTX110 in DIPG;
-- initiate a pilot Phase I clinical study of MTX110 in GBM; and
-- general corporate purposes.
Taking into account available cash resources and the expected Net Proceeds, the Company expects to have sufficient cash resources to fund operations into the first quarter of 2023.

Further Information on the Placing

The Company and Turner Pope entered into a placing agreement ("Placing Agreement"), pursuant to which Turner Pope agreed to use its reasonable endeavours to procure placees pursuant to the Placing. The Placing is not underwritten. Turner Pope has received binding commitments from placees to acquire the Placing Shares at the Issue Price.

The Placing Agreement contains certain warranties and indemnities by the Company in favour of Turner Pope. It also contains provisions entitling Turner Pope to terminate the Placing Agreement prior to Admission, as defined below, if, among other things, a breach of any of the warranties occurs or on the occurrence of an event fundamentally and adversely affecting the position of the Company.

The Placing is conditional upon, inter alia:

(a) the Placing Agreement becoming unconditional in all respects (save for Admission occurring) and not having been terminated in accordance with its terms; and

(b) Admission becoming effective by no later than 8.00 a.m. on 6 July 2021 (or such later time and/or date as the Company and Turner Pope may agree (being not later than 4.30 p.m. on 3 August 2021).

Application for Admission to trading on AIM

Subject to all conditions being met, application will be made for the 35,087,720 Placing Shares to be admitted to trading on AIM ("Admission"). It is expected that settlement of the Placing Shares and Admission will take place at 8.00 a.m. on or about 6 July 2021 and that dealings in the Placing Shares will commence at that time.

When issued, the Placing Shares will be fully paid and will rank pari passu in all respects with the existing ordinary shares.

Total Voting Rights

Upon Admission, the Company's issued share capital will comprise 98,468,387 ordinary shares of 0.1p each with voting rights. The Company does not hold any shares in treasury. Upon Admission this figure of 98,468,387 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Commenting, Stephen Stamp, Midatech CEO and CFO, said: "It has been a busy 13 months since we announced our Strategic Review and restructuring. On 17 June 2021 we announced progress in our R&D pipeline across multiple programmes and breakthrough data on the successful encapsulation of a large molecule protein with Q-Sphera - a world's first. Today's announcement of the Placing gives us the runway to initiate Phase II and Phase I clinical studies of MTX110 in DIPG and GBM, respectively. Our focus now turns to lining up partners for these programmes."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

The person responsible for arranging the release of this announcement on behalf of the Company is Stephen Stamp, Chief Executive Officer and Chief Financial Officer.

For more information, please contact:


Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: [phone]
www.midatechpharma.com

[david gruen] 29/6/2021 08:03

Looks like they've been forward sold. Fully funded. Onwards and upwards.

[dave4545] 29/6/2021 07:39

There's your answer

28.5p placing ouch

[mvp1689] 28/6/2021 14:09

Why is there a lack of movement with this?

[zb27] 25/6/2021 08:53

Now that the big 'breakthrough' has been made, next couple of months could be company defining. News on multiple fronts, funding sorted, licensing deals, milestone payments, working in partnership with other Global Pharmas. Current subsidiary of the Global Healthcare company is working on 3-4 separate projects with Midatech!With their 'Watson Crick' moment, you expect other Global Pharmas to be clamouring all around Midatech, wanting to be part of it. And dare i say it, with the potential of Q-Sphera ($154 billion) and low market cap (£21m), TAKEOVER target.

[zb27] 24/6/2021 11:13

I think once news slowly spreads, this will be absolutely flying high. Similar to last years move, but with the game changing news, will hold and obviously go significantly higher! Any sniff of commercial licensing deals, funding from Global partners etc. A disgraceful move from mm's yesterday, perception is its up big today, however its not really moved. I'm sure they will try every tactic in the book to hold this down, until their chums have loaded! This is only heading one way, and they know it!

[pjmurf] 24/6/2021 10:01

Shhh Dave don't tell em!They might stop chasing beer money and find an innovative company with a cutting edge product worth investing in for much bigger longer term gains.

[dave4545] 24/6/2021 08:54

Classic example of traders being fooled by the uncrossing trade yesterday.

Thinking it's on of the top % risers and chasing it up when it's actually up slightly.

Of course we benefit who were already in.

Funny how there's so many traders have no clue what they are doing

[luckypaul1] 24/6/2021 08:51

Been looking for a day trade and stumbled across this.

[fillipe] 24/6/2021 08:21

36p as the lowest ask on show, as I type.

f

[dave4545] 23/6/2021 17:43

There's a bigger trade at 31p but that is why the price dropped to 32p this morning.

The mm's are clever, they always leave these trades till the end of the day so people get spooked by them.

[zb27] 23/6/2021 17:06

Ha manipulation of the highest order. A UT @ 31p for 58 shares! I think it will sort itself out in the morning. Official close was 35, with a spread of 34-36. It could still be the highest riser lol its so difficult to buy, i reckon this will shoot up very quickly, people will be wondering 'low 30s' jeez what a gift that was!common sense really went up 80% + on compang changing news, then baxk to where it was BEFORE the news came out. Makes no sense. Hopefully finds its real intrinsic value over the coming days/weeks. Next news, will put a rocket launcher up the share price. Should be trading in the ££, the market opportunity is out of this world!

[dave4545] 23/6/2021 16:57

MTPH will be the biggest % riser tomorrow.

Before you say it's a desperate ramp they uncrossed a tiny lot at 31p after the close so the price closed 4p lower than it should.

So in the morning when it opens up at 35p it will show up 4p or about 11% which probably means it's the top riser at 8am unless some penny stock announces fantastic news and opens higher.

[zb27] 23/6/2021 15:29

The way I look at it, even a market cap of just £300m, this is £5. x15.and with last weeks discovery so EASILY doable.Many many companies, with alot less, valued at much higher than £300m!!!

[dave4545] 23/6/2021 15:04

Flying on the nasdaq.

People selling over here lol

[dave4545] 23/6/2021 14:27

A few times this week there has been backwardisation online

It's 34.35 to sell right now and 34.3p to buy

[zb27] 23/6/2021 13:58

NT to buy any significant volume. Therefor buyer having to break up trades in 2k 5k, driving the price higher. Imagine a big buyer wanting 50k 100k, it will go nuts, this will fly up in a flash. Anyway should never be down here in the first place. Looks like everyone bought on news and quickly sold out when it didnt go £1+ in a few hours :) Massive opportunity for real investors who have grasped the enormity of the news released last week.

[jev1] 23/6/2021 13:45

Managed to buy at 34.9.

Happy with that.